CA3010213A1 - Fused quadracyclic compounds, compositions and uses thereof - Google Patents

Fused quadracyclic compounds, compositions and uses thereof Download PDF

Info

Publication number
CA3010213A1
CA3010213A1 CA3010213A CA3010213A CA3010213A1 CA 3010213 A1 CA3010213 A1 CA 3010213A1 CA 3010213 A CA3010213 A CA 3010213A CA 3010213 A CA3010213 A CA 3010213A CA 3010213 A1 CA3010213 A1 CA 3010213A1
Authority
CA
Canada
Prior art keywords
compound
esi
optionally substituted
nmr
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3010213A
Other languages
English (en)
French (fr)
Inventor
Casey Cameron Mccomas
Michael H. Serrano-Wu
Joseph P. Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tabomedex Biosciences Inc
Original Assignee
Tabomedex Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tabomedex Biosciences LLC filed Critical Tabomedex Biosciences LLC
Publication of CA3010213A1 publication Critical patent/CA3010213A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3010213A 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof Pending CA3010213A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04
PCT/US2017/012092 WO2017120164A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA3010213A1 true CA3010213A1 (en) 2017-07-13

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010213A Pending CA3010213A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Country Status (9)

Country Link
US (2) US10059718B2 (enExample)
EP (1) EP3400228B1 (enExample)
JP (1) JP7068185B2 (enExample)
CN (1) CN108779123B (enExample)
AU (1) AU2017205320B2 (enExample)
CA (1) CA3010213A1 (enExample)
ES (1) ES2915901T3 (enExample)
TW (1) TWI730027B (enExample)
WO (1) WO2017120164A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
WO2022150707A1 (en) * 2021-01-11 2022-07-14 Tabomedex Biosciences, Inc. Fused quadracyclic compounds, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
US20160066387A1 (en) * 2013-03-22 2016-03-03 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Also Published As

Publication number Publication date
EP3400228A4 (en) 2019-08-14
JP7068185B2 (ja) 2022-05-16
AU2017205320A1 (en) 2018-07-05
EP3400228B1 (en) 2022-04-13
TW201726681A (zh) 2017-08-01
JP2019501971A (ja) 2019-01-24
AU2017205320B2 (en) 2021-06-24
US10562909B2 (en) 2020-02-18
WO2017120164A1 (en) 2017-07-13
US20170190713A1 (en) 2017-07-06
ES2915901T3 (es) 2022-06-27
US20180319809A1 (en) 2018-11-08
TWI730027B (zh) 2021-06-11
US10059718B2 (en) 2018-08-28
CN108779123B (zh) 2025-08-19
EP3400228A1 (en) 2018-11-14
CN108779123A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
JP5959541B2 (ja) Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
EP3766885B1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
SK287273B6 (sk) N-Substituované diazabicyklické zlúčeniny, farmaceutický prípravok s ich obsahom a ich použitie
HUE031980T2 (en) Condensed heterocyclic compounds as protein kinase inhibitors
AU2018269743A1 (en) Kinase inhibitors and uses thereof
TW202237597A (zh) 新型egfr降解劑
CN112584898B (zh) P2x3受体拮抗剂
JP2018516970A (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
US10562909B2 (en) Fused quadracyclic compounds, compositions and uses thereof
TW202417458A (zh) 調節her2的化合物及方法
CA3080623C (en) Compound having erk kinase inhibitory activity and use thereof
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK40045028B (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
HK40045028A (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
HK1254661B (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
OA18469A (en) Tricyclic compounds and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230

EEER Examination request

Effective date: 20211230